

1 PolyQ expansion does not alter the Huntingtin-HAP40 complex

2

3 **Bin Huang^{1,10}, Qiang Guo^{2,3,10}, Marie L. Niedermeier^{4,5,10}, Jingdong Cheng⁶, Tatjana Engler¹, Melanie**
4 **Maurer⁷, Alexander Pautsch⁷, Wolfgang Baumeister², Florian Stengel^{4,5,*}, Stefan Kochanek^{1,*}, Rubén**
5 **Fernández-Busnadiego^{2,8,9,11,*}**

6 ¹Department of Gene Therapy, Ulm University, 89081 Ulm, Germany

7 ²Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried,
8 Germany

9 ³State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences and Peking-Tsinghua
10 Center for Life Sciences, Peking University, 100871 Beijing, China

11 ⁴Department of Biology, University of Konstanz, 78457 Konstanz, Germany

12 ⁵Konstanz Research School Chemical Biology, University of Konstanz

13 ⁶Gene Center, Department of Biochemistry and Center for integrated Protein Science Munich, Ludwig-
14 Maximilians University, 81377 Munich, Germany

15 ⁷Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an
16 der Riß, Germany

17 ⁸Institute of Neuropathology, University Medical Center Göttingen, 37099 Göttingen, Germany.

18 ⁹Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells"
19 (MBExC), University of Göttingen, 37075 Göttingen, Germany

20

21 ¹⁰**Theses authors contributed equally**

22 ***Correspondence**

23 florian.stengel@uni-konstanz.de (F.S.)

24 stefan.kochanek@uni-ulm.de (S.K.)

25 ruben.fernandezbusnadiego@med-uni.goettingen.de (R.F.-B.)

26

27 **¹¹Lead Contact**

28 ruben.fernandezbusnadiego@med-uni.goettingen.de (R.F.-B.)

29 **Summary**

30 The abnormal amplification of a CAG repeat in the gene coding for huntingtin (HTT) leads to Huntington
31 disease (HD). At the protein level, this translates into the expansion of a poly-glutamine (polyQ) stretch
32 located at the HTT N-terminus, which renders it aggregation-prone by unknown mechanisms. Here we
33 investigated the effects of polyQ expansion on HTT in a complex with its stabilizing interaction partner
34 huntingtin-associated protein 40 (HAP40). Surprisingly, our comprehensive biophysical, crosslinking mass
35 spectrometry and cryo-EM experiments revealed no major differences in the conformation of HTT-HAP40
36 complexes of various polyQ length, including 17QHTT-HAP40 (wild type), 46QHTT-HAP40 (typical polyQ
37 length in HD patients) and 128QHTT-HAP40 (extreme polyQ length). Thus, HTT polyQ expansion does not
38 alter the global structure of HTT when associated with HAP40.

39 **Keywords**

40 Huntingtin; Huntington's disease; polyglutamine expansion; cryo-electron microscopy; crosslinking mass
41 spectrometry

42

43 Introduction

44 Huntingtin (HTT) is a large protein (348 kDa) involved in a wide variety of cellular processes, including
45 transcriptional regulation, vesicular transport, endocytosis and autophagy (Saudou and Humbert, 2016).
46 The expansion of a CAG repeat in the first exon of the *HTT* gene translates into an expanded poly-
47 glutamine (polyQ) repeat at the N-terminus of HTT and causes Huntington's disease (HD). HD is a
48 devastating neurodegenerative syndrome characterized by uncontrolled movements (chorea), emotional
49 instability and cognitive impairment (Bates et al., 2015; Finkbeiner, 2011). The age of HD onset correlates
50 with the length of HTT polyQ repeat, suggesting an important pathological role of this amino acid stretch.
51 Furthermore, polyQ expansion renders N-terminal fragments of HTT aggregation-prone *in vitro* and *in vivo*
52 (Scherzinger et al., 1997), and similar fragments form inclusion bodies in the brain of HD patient (Difiglia
53 et al., 1995). The effects of polyQ expansion on full length HTT are less well understood, but recent studies
54 reported some conformational changes (Jung et al., 2020; Vijayvargia et al., 2016). However, only low-
55 resolution structures of polyQ-expanded HTT were reported, limiting detailed understanding of the
56 effects of polyQ expansion.

57 We have recently shown that the formation of a complex with huntingtin-associated protein 40 (HAP40),
58 a very abundant cellular binding partner of HTT, dramatically reduces the structural flexibility of HTT,
59 allowing structure determination by cryo-electron microscopy (cryo-EM) (Guo et al., 2018). The formation
60 of this complex may be implicated in the recruitment of HTT to Rab5-positive endosomes (Pal et al., 2006).
61 The HTT-HAP40 complex structure revealed that HTT is a largely alpha-helical protein, with most helices
62 arranged in tandem repeats (Guo et al., 2018). HTT is divided in three major domains. The N- and C-
63 terminal domains ("N-HEAT" and "C-HEAT") are rich in HEAT (huntingtin, elongation factor 3, protein
64 phosphatase 2A and lipid kinase TOR) repeats arranged in a solenoid fashion. These domains are
65 connected by a smaller bridge domain. HAP40 is also largely α -helical and has mainly a tetratricopeptide
66 repeat (TPR)-like organization. The cryo-EM structure revealed only weak connections between the
67 domains, explaining HTT's conformational flexibility. In the complex with HAP40 this flexibility is
68 counteracted by HAP40 binding within a cleft, contacting the N-HEAT and C-HEAT domains mainly by
69 hydrophobic interactions and the bridge domain by electrostatic interactions. Besides these domains,
70 several presumably unfolded regions, including the polyQ stretch, were not resolved in the structure.

71 Here we used the HTT-HAP40 complex as a tool to examine the effects of pathological polyQ expansion
72 on HTT structure. We cloned and expressed three complexes: 17QHTT-HAP40 (WT), 46QHTT-HAP40
73 (typical polyQ length in HD patients) and 128QHTT-HAP40 (extreme polyQ length). Combining biophysical

74 techniques, cross-linking mass spectrometry and high-resolution structural determination by cryo-EM, we
75 conclude that the polyQ length does not substantially influence the global architecture of the HTT-HAP40
76 complex.

77

78 Results

79 Purification, biochemical and biophysical characterization of HTT-HAP40

80 Previously, we described the production of human full length 17QHTT as a complex with HAP40 in a
81 human cell line (Guo et al., 2018). To also enable the production and analysis of polyQ-expanded HTT, we
82 generated additional human cell lines expressing full length HTT containing either 46 (46QHTT) or 128
83 glutamines (128QHTT). In these cells, HTT was expressed after induction with doxycycline, while HAP40
84 was under constitutive promoter control. We used a C-terminal Strep-tag on HAP40 for affinity
85 purification of the HTT-HAP40 complexes, followed by size-exclusion chromatography (SEC).

86 Independent of their polyQ length, all HTT-HAP40 complexes eluted in a practically identical manner as a
87 symmetric narrow peak and in similar yields (Figure 1A). Coomassie staining and Western blot analyses
88 confirmed the purity of the materials, the presence of HTT and HAP40 in the complexes and the
89 differences in polyQ length (Figure 1B, C). Both differential scanning fluorimetry (Figure 1D) and
90 differential intrinsic tryptophan scanning fluorimetry (Figure 1E) showed very similar and sharp unfolding
91 profiles and nearly identical melting points, indicating that the stabilities of the three complexes were
92 identical. Altogether, these data show that HTT polyQ expansion does not induce major changes in the
93 shape, stability and aggregation propensity of HTT-HAP40 complexes.

94 Cryo-EM analysis of polyQ-expanded HTT-HAP40 complexes

95 To further investigate possible structural rearrangements, we analyzed polyQ-expanded HTT-HAP40
96 complexes by cryo-EM (Figure 2). The structures of 46QHTT-HAP40 (Figure 2A) and 128QHTT-HAP40
97 (Figure 2C) were determined with global resolutions of 3.6 Å and 4.1 Å respectively (Figure S 1, Table S 1).
98 No density was observed for the disordered insertions that were absent from the 17QHTT-HAP40
99 structure, including the polyQ stretch. Based on these maps, atomic models were built using energy
100 minimization. Consistent with our biophysical data, the overall architectures of the 17QHTT-HAP40 (Guo
101 et al., 2018) (PDB-6EZ8), 46QHTT-HAP40 and 128QHTT-HAP40 complexes were identical: two HEAT
102 repeats domains linked by a bridge domain, with HAP40 binding in the cleft between the HTT domains.
103 For a more detailed comparison, we calculated the root-mean-square deviation (RMSD) of C α between
104 the WT and polyQ-expanded atomic models (Figure 2B, D). The average RMSD were 0.89 Å (17Q vs 46Q)
105 and 1.29 Å (17Q vs 128Q) respectively. The maximum RMSD was smaller than 3 Å in both cases, indicating
106 that the structures are identical at the current resolution. Therefore, our cryo-EM data conclusively show
107 that polyQ expansion has no noticeable influence on the architecture of the HTT-HAP40 complex.

108 Crosslinking mass spectrometry

109 We reasoned that WT and polyQ-expanded HTT-HAP40 complexes could also differ in unstructured
110 regions not resolved in the cryo-EM structures. We addressed this possibility using chemical crosslinking
111 coupled to mass spectrometry (XL-MS). Isotopically labelled disuccinimidyl suberate (DSS) was used to
112 crosslink lysine residues in 17QHTT-HAP40, 46QHTT-HAP40 and 128QHTT-HAP40 complexes. XL-MS uses
113 covalent bonds formed by crosslinking reagents in order to identify crosslinking sites by MS that reflect
114 the spatial proximity of regions within a given protein (intralink) or between different proteins or subunits
115 in a protein complex (interlink). Additional information on the accessibility of a specific lysine residue can
116 be obtained from crosslinks that react on one side with the protein and hydrolyse on the other side
117 (monolink). Approximately 65 % of the 123 lysines present in HTT were accessible to DSS (77 lysines in
118 17QHTT, 75 in 46QHTT and 88 in 128QHTT; Table S 2). In all complexes, 52 lysines encompassing the whole
119 length of HTT were modified by monolinks, while five monolinks were identified in at least two of the
120 complexes and 14 were unique to a single complex (Figure S3 and Table S 2). Unique monolinks did not
121 show any specific localization, suggesting that they were due to experimental variabilities.

122 We further identified 78 intra-HTT crosslinks, of which 49% were present in all three complexes (Figure 3,
123 Figure S3 and Table S 2). Additionally, 14 crosslinks were common to two complexes and 26 were found
124 only in one (Figure 3, Figure S3 and Table S 2). Many of the crosslinks involved unstructured regions not
125 resolved in the cryo-EM structures, but no crosslinks were detected within HTT exon 1 (Figure S 2). In
126 general, the crosslinks built up four main interaction clusters within HTT (Figure 3, Figure S3): i) N-HEAT
127 domain, ii) N-HEAT to bridge domain, iii) N-HEAT to C-HEAT domain and iv) C-HEAT domain. The intra-
128 domain (N-HEAT and C-HEAT) crosslinks were extremely similar for all complexes, while the inter-domain
129 connectivity (N-HEAT to bridge and C-HEAT domains) was overall highly similar as well, but exhibited some
130 small differences. However, as slight variations in the detected crosslinks are common even between
131 replicate measurements (Table S2), our data strongly indicates no significant differences between the
132 overall HTT crosslinking pattern (intra- and monolinks) of the different HTT-HAP40 complexes (Figure S3).

133 In terms of inter-protein interactions (i.e. crosslinks between lysines within HTT and HAP40), 13 unique
134 crosslinks were identified between HTT and HAP40, of which 9 were common for all three complexes,
135 three were identified in two different complexes and one was uniquely identified in 46QHTT-HAP40
136 (Figure S 3 and Table S 2). Again, such a high overlap between the detected HTT-HAP40 crosslinks strongly
137 indicates that the overall interaction pattern of the two proteins is not affected by HTT polyQ length
138 (Figure S3). As residues crosslinked by DSS can be up to ~30 Å apart (Iacobucci et al., 2019), all detected

139 intra-HTT and inter-HTT-HAP40 crosslinks were fully compatible with our cryo-EM structures, reinforcing
140 the consistency of our results.

141 Taken together, our biophysical, cryo-EM and crosslinking mass spectrometry data converge to rule out a
142 major influence of HTT polyQ length on the architecture of the HTT-HAP40 complex.

143

144 Discussion

145 The biophysical mechanisms by which polyQ expansion leads to HTT aggregation in HD remain poorly
146 understood. Previous studies suggested that HTT could adopt different 3D conformations, some of which
147 would be influenced by polyQ expansion (Pardo et al., 2010; Saudou and Humbert, 2016; Vijayvargia et
148 al., 2016). At the same time, polyQ expansion does not result in an abrupt conformational change of the
149 HTT N-terminus (Bravo-Arredondo et al., 2018; Newcombe et al., 2018; Warner et al., 2017). A recent
150 study showed cryo-EM analyses at ~ 10 Å resolution of recombinant 23QHTT and 78QHTT upon GraFix
151 stabilization, in combination with XL-MS, small-angle X-ray scattering and hydrogen-deuterium exchange
152 (Jung et al., 2020). This study indicated that apo HTT (i.e. HTT not bound to HAP40), has a flexible and
153 modular character. While no significant differences within the major HTT domains were detected in
154 23QHTT and 78QHTT compared to the 17QHTT-HAP40 structure (Guo et al., 2018), changes in the relative
155 positions between HTT domains resulted in a more extended conformation of 23QHTT and in particular
156 78QHTT.

157 In contrast, our high-resolution cryo-EM structure analyses show no differences in the overall architecture
158 of the HTT-HAP40 complex irrespective of polyQ length. Although the HTT N-terminal exon 1 fragment
159 may be more compacted with increasing polyQ length (Bravo-Arredondo et al., 2018; Newcombe et al.,
160 2018; Warner et al., 2017), it was not visible in any of the structures, possibly due to the flexibility of the
161 proline-rich region. These data also imply that the exon 1 fragment has no scaffolding function within the
162 complex core, rationalizing why polyQ length does not affect the overall HTT-HAP40 structure.

163 Our structural view that HAP40 shields hydrophobic patches on opposite faces of the N-HEAT and C-HEAT
164 domains independently of the polyQ length is consistent with our DSF results, thermal unfolding behavior
165 and crosslink mass spectrometry. Furthermore, a large proportion of the intra-HTT crosslinks detected in
166 our samples were also found in apo HTT with wild type and expanded polyQ lengths (Vijayvargia et al.,
167 2016). Therefore, while polyQ expansion may influence the conformation of apo HTT, the stabilization of
168 HTT conformation by HAP40 binding (Guo et al., 2018) is independent of polyQ length.

169 The increased flexibility of apo HTT may also explain its elution characteristics upon SEC and its
170 sedimentation behavior in analytical ultracentrifugation (Huang et al., 2015). Those experiments revealed
171 that a significant proportion of wild type HTT with normal polyQ length formed dimers, higher-order
172 oligomers and aggregates. Under these *in vitro* conditions, oligomer and aggregate formation was further
173 enhanced by increasing polyQ length (Huang et al., 2015). However, very little oligomer and aggregate

174 formation was observed for 46QHTT and 128QHTT when purified as complex with HAP40. Thus, HTT-
175 HAP40 complexes appear highly stable independent of HTT polyQ length.

176 Although HAP40 is an abundant interactor of HTT (Guo et al., 2018; Peters and Ross, 2001), there is little
177 experimental information on HAP40 function(s). The HTT-HAP40 complex may be involved in endosomal
178 function (Pal et al., 2006). We recently reported that HAP40 and HTT likely co-evolved in unikonts and
179 that the HTT-HAP40 interaction is evolutionarily conserved, suggesting its functional importance
180 (Seefelder et al., 2020). We also observed that HAP40 steady-state protein levels are directly dependent
181 on HTT (both wild type and mutant), and that the otherwise short half-life of HAP40 is strongly increased
182 by the interaction with HTT (Huang et al., submitted). Since it was not possible to reconstitute the HTT-
183 HAP40 complex from purified monomers *in vitro* (Guo et al., 2018), we hypothesize that the complex is
184 established in cells early after translation or even co-translationally, resulting in a rather rigid structure
185 (Guo et al., 2018 and this report).

186 Altogether, we show that HTT polyQ expansion does not alter HTT structure within the HTT-HAP40
187 complex. Apo HTT, i.e. not bound to HAP40, may be more flexible and undergo subtle conformational
188 changes upon polyQ expansion (Jung et al., 2020). Whether such rearrangements are related to the
189 described loss- or gain-of-function phenotypes of mutant full length HTT in HD (Cisbani and Cicchetti,
190 2012; Zuccato et al., 2010) requires further investigation.

191

192

193

194 **Acknowledgments**

195 We thank Günter Pfeifer and Jürgen Plitzko for electron microscopy support, Florian Beck for help with
196 image processing. This work has been funded by the CHDI Foundation, the Huntington-Stiftung, the Max
197 Planck Society, the European Commission (grant FP7 GA ERC-2012-SyG_318987–ToPAG to W.B.), the
198 Konstanz Research School Chemical Biology and the Deutsche Forschungsgemeinschaft (DFG, German
199 Research Foundation – project number 412854449 to S.K., Emmy Noether grant STE 2517/1-1 to F.S. and
200 Germany’s Excellence Strategy grant EXC 2067/1- 390729940 to R.F.-B.). M.N. is grateful for funding from
201 the Zukunftskolleg.


202 **Author Contributions**

203 B.H., S.K., M.N., F.S., A.P., W.B., Q.G., R.F.-B designed experiments. M.M., A.P., H.B. performed DSF and
204 nanoDSF studies. M.N. performed crosslinking studies. H.B. prepared HTT-HAP40 samples for cryo-EM
205 and performed biochemical analyses together with T.E. Q.G. performed cryo-EM work. J.C. built the
206 atomic model. Q.G., J.C. and R.F.-B. analyzed the structure. B.H., S.K., M.N., F.S., Q.G., J.C., A.P., R.F.-B.
207 analyzed data. B.H., Q.G., M.N. prepared figures. B.H., S.K., M.N., F.S., A.P., W.B., Q.G., R.F.-B wrote the
208 manuscript. All authors commented on the manuscript.

209 **Declaration of Interests**

210 The authors declare no competing interests

211 **Figures and Figure Legends**



212

213 **Figure 1: Purification, biochemical and biophysical characterization of HTT-HAP40 complexes.**

214 **(A)** SEC elution profiles of HTT-HAP40 complexes differing in HTT polyQ length. The HTT-HAP40 complexes
 215 were purified from HEK293-based human cells co-expressing FLAG-tagged HTT with 17Q (17QHTT), 46Q
 216 (46QHTT) or 128Q (128QHTT), respectively, together with Strep-tagged HAP40. Cleared cell lysates were
 217 incubated with Strep-Tactin beads, washed and bound proteins were eluted with desthiobiotin prior to
 218 loading on a Superose 6 10/300 increase column.

219 **(B)** Coomassie staining of the main peak of the different HTT-HAP40 eluates shown in (A).

220 **(C)** Western Blot analyses of HTT-HAP40 eluates after affinity purification and SEC, using antibodies
 221 detecting HTT (upper two rows), polyQ (middle) and HAP40 (lower two rows).

222 **(D, E)** Thermal unfolding of the different HTT-HAP40 complexes. Melting curves and melting points were
223 obtained by differential scanning fluorimetry (DSF) (D) and nano differential scanning fluorimetry
224 (nanoDSF) (E). Melting temperatures are indicated. One of three measurements is shown.
225





Figure 2: Architecture of polyQ expanded HTT-HAP40 complexes by cryo-EM.

(A, C) Reconstructed density maps of 46QHTT-HAP40 (A) and 128QHTT-HAP40 (C) filtered according to local resolution and shown as surface representation. The HTT N-HEAT domain, bridge domain and C-HEAT domains are respectively colored in blue, yellow and maroon. HAP40 is colored in purple. Stars indicate the most N-terminal region of HTT resolved.

(B, D) Atomic models of 46QHTT-HAP40 (B) and 128QHTT-HAP40 (D) are shown in ribbon representation, colored according to their RMSD with 17QHTT-HAP40 (Guo et al., 2018) (PDB-6ZE8).

See also Figure S 1 and Table S 1.



235

236 **Figure 3: Effects of polyQ expansion on intra-HTT crosslink patterns of HTT-HAP40 complexes.**

237 **(A, B)** Comparative representation of all intra-HTT crosslinks identified within three different HTT-HAP40
238 complexes, namely 17QHTT-HAP40 vs 46QHTT-HAP40 (A) and 17QHTT-HAP40 vs 128QHTT-HAP40 (B). A
239 uniform numbering scheme based on the 17QHTT sequence was used. Crosslinks common to all three
240 complexes are represented by thick, black solid lines. Crosslinks identified in only two of the complexes
241 are represented by thin solid lines (17QHTT and 46QHTT, black; 17QHTT and 128QHTT dark grey; 46QHTT
242 and 128QHTT, light grey). Crosslinks identified in only one of the complexes are depicted by dotted lines
243 (17QHTT, black; 46QHTT, dark grey; 128QHTT light grey). Only high-confidence crosslinks that were
244 reliably identified at least in two out of three biological replicates are shown (see methods for details).
245 The HTT N-HEAT domain, bridge domain and C-HEAT domains are colored in blue, yellow and maroon,
246 respectively. HAP40 is colored in purple.

247 See also Figure S 2, Figure S 3 and Table S 2.

248 **STAR Methods**

249 **RESOURCE AVAILABILITY**

250 *Lead contact*

251 Requests for resources and reagents should be addressed to the lead contact Prof. Rubén Fernández-
252 Busnadiego, ruben.fernandezbusnadiego@med-uni.goettingen.de

253 *Materials Availability*

254 Plasmids and cell lines generated in this study will be provided upon request.

255 *Data and Code Availability*

256 The cryo-EM maps of 46QHTT-HAP40 and 128QHTT-HAP40 have been deposited at the Electron
257 Microscopy Data Bank under accession codes EMD-30911 and EMD-30912, respectively. The modeled
258 structures of the 46QHTT-HAP40 complex and 46QHTT-HAP40 have been deposited at the Protein Data
259 Bank under accession codes 7DXJ and 7DXK. The cryo-EM maps of 17QHTT-HAP40 have previously been
260 deposited under accession codes EMD-3984 and PDB-6EZ8, respectively.

261 The MS raw files, databases containing protein fasta sequences for analysis with xQuest as well as
262 xQuest result files have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaino et
263 al., 2016) partner repository with the dataset accession number PXD018451 (username:
264 reviewer33889@ebi.ac.uk; password: fnbVMbIT).

265 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

266 Human HEK293-based cell lines for production of HTT-HAP40 complexes were propagated in MEM Alpha
267 medium (GIBCO, #22561-021), supplemented with 10 % fetal bovine serum (GIBCO, #10270-106), 1 %
268 Pen/Strep/Glutamine (GIBCO, #10378-016), 50 ug/ml Geneticin (GIBCO, #10131-027), 15 ug/ml
269 Hygromycin (Invitrogen, #10687010) and 1 ug/ml Puromycin (GIBCO, #11138-03). Induction of HTT
270 expression was performed with Doxycycline (Clontech, #631311) at a final concentration of 1ug/ml.

271

272 **METHOD DETAILS**

273 **Antibodies**

274 The following antibodies were used: anti-FLAG M2 (Sigma-Aldrich F3165), anti-HTT N18 (Santa Cruz SC-
275 8767), anti-polyQ (Sigma 3B5H10), anti-HAP40 (Santa Cruz SC-69489) and anti-Strep (IBA 2-1507-001).

276 **Cell lines**

277 B1.21 cells (Huang et al., 2015) are based on HEK293 cells and express FLAG-His tagged human full length
278 17QHTT upon induction with doxycycline (Dox). B1.21-HAP40 cells (Guo et al., 2018) additionally co-
279 express human HAP40 constitutively. C2.6 cells (Huang et al., 2015) are based on HEK293 cells and express
280 FLAG-His tagged human full length mutant 46QHTT.

281 HTT128 cells were generated in a similar manner as B1.21 cells. A cDNA coding for 128QHTT with C-
282 terminal fusion to a FLAG-His affinity tag was cloned into the vector pTRE-tight-BI-AcGFP1 (Clontech) for
283 expression of 128QHTT upon induction with Dox. The resulting plasmid pTRE-HTT128Q was verified by
284 restriction analysis and sequencing. HEK293 Tet-ON cells (Clontech) were co-transfected with linearized
285 pTRE-HTT128Q together with a plasmid expressing a hygromycin resistance gene. Positive cell clones were
286 selected by addition of hygromycin to the culture medium. Monoclonal HTT128 cell lines were obtained
287 by limited dilution of positive cell clones.

288 C.6-HAP40TS and HTT128-HAP40TS cells were generated in a similar manner as B1.21-HAP40 cells. In brief,
289 C2.6 and HTT128 cells were co-transfected with plasmid pBSK/2-CMV-HAP40-TS together with a linearized
290 plasmid expressing a puromycin resistance gene. Positive cell clones were selected by addition of
291 puromycin to the culture medium. The resulting stable cell lines (C2.6-HAP40TS and HTT128-HAP40TS)
292 express, in a constitutive manner, HAP40 C-terminally fused to a Strep affinity tag and mutant HTT
293 (46QHTT and 128QHTT, respectively) upon induction with Dox. These cell lines were used for production
294 of mutant 46QHTT-HAP40 and 128QHTT-HAP40 complexes, respectively.

295 All generated cell lines were tested negative for mycoplasma by PCR. Induction of mutant HTT expression
296 by Dox was confirmed by Western blot analysis.

297 **Purification of 17QHTT-HAP40, 46QHTT-HAP40 and 128QHTT-HAP40 complexes**

298 The HTT-HAP40 complexes were purified as described (Guo et al., 2018). In brief, 1.2×10^9 B1.21-HAP40TS
299 cells, C2.6-HAP40 cells or HTT128-HAP40 cells were harvested 72 h after induction with Dox by
300 centrifugation at 400 g for 10 min. Cells were lysed in 25 mM HEPES, 300 mM NaCl, 0.5 % Tween 20,

301 protease inhibitor, pH 8.0, by rotation at 4° C for 30 min followed by centrifugation of the cell lysate at
302 30,000 g and clearance by filtration through a 0.2 µm filter. The filtrate was incubated with Strep beads
303 (IBA) for 2-3 h at 4 °C. After washing three times with 25 mM HEPES, 300 mM NaCl, 0.02% Tween 20, pH
304 8.0, bound proteins were eluted with 25 mM HEPES, 300 mM NaCl, 0.02% Tween 20, 2.5 mM
305 Desthiobiotin, pH 8.0. The eluate was concentrated using Amicon filters.

306 The HTT-HAP40 complex was further purified by size exclusion chromatography (SEC) using a Superose 6
307 10/300 increase column (GE Healthcare) in running buffer 25 mM HEPES, 300 mM NaCl, 0.1% CHAPS and
308 1 mM DTT, pH 8.0. HTT-HAP40 eluted in one narrow-based peak and was concentrated with Amicon ultra
309 100 kDa filters (Millipore). The purity of purified HTT-HAP40 complex was analysed by SDS-PAGE and silver
310 Coomassie-Blue staining. The integrity of HTT and HAP40 in the HTT-HAP40 complex was confirmed by
311 Western blot analysis.

312 [Protein thermostability measurement by differential scanning fluorimetry \(DSF\)](#)

313 The thermostability of HTT-HAP40 complexes was assessed by DSF (Vedadi et al., 2006). Protein unfolding
314 was monitored by the increase in the fluorescence of SYPRO Orange (Invitrogen). Prior to use, a 100 mM
315 stock of the dye (stored at -20°C) was diluted 1:20 in DMSO and directly added to the sample to a final
316 concentration of 125 µM. The proteins were diluted in sample buffer (25 mM HEPES, 300 mM NaCl, 0.1%
317 CHAPS, 1 mM DTT and 10% glycerol) to concentrations of 0.2 mg/ml. The samples were heated up with a
318 ramp rate of 1 °C/min over a temperature range of 15-95 °C using the qPCR System MX 3005 P (Stratagene).
319 Measurements were performed in triplicate. Unfolding transition temperatures (T_m) were automatically
320 determined by the software of the qPCR machine.

321 [Protein thermostability measurement by nanoDSF](#)

322 Protein thermostability was further assessed using low volume differential intrinsic tryptophan scanning
323 fluorimetry (nanoDSF) (Alexander et al., 2014). Here, the intrinsic fluorescence of protein thryptophan
324 residues was directly monitored to eliminate artefacts caused by labeling or modifying the protein. The
325 tested proteins were diluted in sample buffer (25 mM HEPES, 300 mM NaCl, 0.1% Chaps, 1 mM DTT and
326 10% glycerol) to a final concentration of 0.3 mg/ml. 10 µl samples were manually loaded into nanoDSF
327 Grade Standard Capillaries (NanoTemper Technologies) and transferred to a Prometheus NT.48 nanoDSF
328 device (NanoTemper Technologies). Samples were heated with a linear ramp rate of 1 °C/min over a
329 temperature range from 20-95 °C. Unfolding profiles were determined from changes in the emission
330 wavelengths of tryptophan fluorescence at 330 nm, 350 nm and their ratios. Data was analyzed with the

331 Prometheus PR. Control software (NanoTemper Technologies). Measurements were performed in
332 triplicates.

333 Cryo-EM sample preparation, data acquisition and image processing

334 Cryo-EM samples were prepared and processed as described (Guo et al., 2018). Purified HTT-HAP40
335 complexes were diluted to 0.5 mg/ml with 25 mM HEPES, 300 mM NaCl, 0.025% CHAPS, 1 mM DTT. 4 μ l
336 of samples were applied to R2/4 Quantifoil gold grids with suspended monolayer graphene (Graphenea)
337 and vitrified by plunge-freezing into a liquid ethane/propane mixture using Vitrobot Mark IV (FEI). Data
338 collection was performed on a Titan Krios microscope operated at 300 kV and equipped with a Gatan GIF
339 Quantum energy filter. The calibrated magnification was 105,000X in EFTEM mode, corresponding to a
340 pixel size of 1.35 Å. Images were collected by a K2 Summit direct electron camera (Gatan) using counting
341 mode, with a dose rate of 4 electrons/Å²/s. Each exposure (8 s exposure time) comprised 16 sub frames,
342 amounting to a total dose of 32 electrons/Å². Data was recorded using SerialEM software (Mastronarde,
343 2005) and custom macros. Defocus values ranged from -1.4 to -3 μ m. 1127 and 1438 movie stacks were
344 collected for 46QHTT-HAP40 and 128QHTT-HAP40 samples respectively.

345 Raw frame stacks were subjected to beam-induced motion correction using MotionCor2 (Zheng et al.,
346 2017). Most further processing was performed using RELION (Scheres, 2012). The contrast transfer
347 function parameters for each micrograph were determined with CTFIND4 (Rohou and Grigorieff, 2015),
348 and all micrographs with a resolution limit worse than 4 Å were discarded. Particles were initially picked
349 with Gautomatch (http://www.mrc-lmb.cam.ac.uk/kzhang/Gautomatch/Gautomatch_Brief_Manual.pdf)
350 using a sphere as template, and extracted with a 160-pixel by 160-pixel box. Reference-free 2D class
351 averaging was performed reiteratively, keeping only particles contributing to well-resolved 2D averages.
352 The resulting particle subsets were used for further three-dimensional classification. The classes with
353 identical detailed features were merged for further auto-refinement to produce the final density map
354 with an overall resolution of 3.6 Å and 4.1 Å for 46QHTT-HAP40 and 128QHTT-HAP40, respectively (Figure
355 S 1, Table S 1). The resolution estimation was based on the gold-standard Fourier shell correlation method
356 using the 0.143 criterion (Scheres and Chen, 2012). All density maps were sharpened by applying
357 temperature factor that was estimated using post-processing in RELION. For visualization, the density
358 maps were filtered based on the local resolution determined using half-reconstructions as input maps.

359 Model building

360 Modeling of 46QHTT-HAP40 and 128QHTT-HAP40 complexes was performed in COOT (Emsley and
361 Cowtan, 2004), using 17QHTT-HAP40 (Guo et al., 2018) as starting model. Regions (1-90, 323-342, 403-
362 660, 960-977, 1049-1057, 1103-1120, 1158-1222, 1319-1347, 1372-1418, 1504-1510, 1549-1556, 1714-
363 1728, 1855-1881, 2063-2091, 2325-2347, 2472-2490, 2580-2582, 2627-2660, 2681-2687, 2926-2944 and
364 3099-3138) of HTT and regions (1-41, 217-257, 300-313 and 365-371) of HAP40 were not built in the final
365 model, as no well-resolved densities were present in the map. Maps refinements were carried out using
366 Phenix.real_space_refine (Adams et al., 2010) against the respective overall map at resolution of 3.6 Å
367 (46QHTT-HAP40) and 4.1 Å (128QHTT-HAP40), with secondary structure and Ramachandran restraints. The
368 final models were validated using MolProbity (Chen et al., 2010).

369 The 46QHTT-HAP40 and 128QHTT-HAP40 models were aligned to the 17QHTT-HAP40 model before
370 analysis. Pairwise C α RMSD was calculated using the PyMOL (Schrödinger) script rmsd_b.py (available at
371 <http://pldserver1.biochem.queensu.ca/~rlc/work/pymol/>). Maps and models were visualized using
372 Chimera (UCSF).

373 Chemical crosslinking coupled to mass spectrometry

374 Protein complexes were crosslinked and measured essentially as described (Leitner et al., 2014). In short,
375 40 μ g of equimolar mixtures of HTT and HAP40 (0.7 μ g / μ L stored in 25 mM HEPES, pH 7.4, 300 mM NaCl,
376 0.05 % CHAPS, 1 mM DTT and 10 % glycerol) were crosslinked by addition of H12/D12 disuccinimidyl
377 suberate (DSS) (Creative Molecules) at a final ratio of 2.5 nmol DSS per 1 μ g protein for 30 min at 37 °C
378 while shaking at 650 rpm in a Thermomixer (Eppendorf). After quenching by addition of ammonium
379 bicarbonate to a final concentration of 50 mM and incubation for 10 min at 37 °C, samples were
380 evaporated to dryness, dissolved in 8 M urea, reduced with TCEP (final concentration of 2.5 mM),
381 alkylated with iodoacetamid (final concentration of 5 mM) and digested overnight with trypsin (Promega
382 V5113) in 1 M urea at an enzyme-to-substrate ratio of 1:40. Digested peptides were separated from the
383 solution and retained by a solid phase extraction system (SepPak, Waters) and subsequently enriched by
384 SEC on an ÄKTAmicro chromatography system (GE Healthcare) using a Superdex™ Peptide 3.2/300
385 column (GE Healthcare) at a flow rate of 50 μ L/min of the mobile phase (water/acetonitrile/trifluoroacetic
386 acid 70 %/30 %/0.1 %, vol/vol/vol). UV absorption at a wavelength of 215 nm was used for monitoring the
387 separation. The eluent was collected in fractions of 100 μ L in a 96-well plate. The three fractions
388 1.0 – 1.1 mL, 1.1 – 1.2 mL and 1.2 – 1.3 mL were collected, dried and further analyzed by LC-MS/MS.

389 Sample amounts fractionated by SEC were normalized and re-dissolved in an appropriate volume of MS
390 buffer (acetonitrile/formic acid 5 %/0.1 %, vol/vol) according to their UV signal (at 215 nm) prior to liquid
391 chromatography (LC)-MS/MS analysis on an Orbitrap Fusion Tribrid mass spectrometer (Thermo
392 Scientific).

393 Data were searched using *xQuest*. Crosslinking was performed in biological triplicates and each sample
394 was additionally measured in technical duplicates. Crosslinks were only considered during structural
395 analysis, if they were identified in at least 2 of 3 biological replicates with $\Delta S < 0.95$, Id score ≥ 25 and
396 at least one with an assigned false discovery rate (FDR) as calculated by *xProphet* below 0.05. Identified
397 crosslinks were visualized by XiNET (Combe et al., 2015).


398 A list of all identified links can be found in Table S 2.

399 LC-MS/MS analysis

400 Peptides were separated on an EASY-nLC 1200 (Thermo Scientific) system equipped with a C18 column
401 (Acclaim PepMap 100 RSLC, length 15 cm, inner diameter 50 μm , particle size 2 μm , pore size 100 \AA ,
402 Thermo Scientific). Peptides were eluted at a flow rate of 300 nL/min using a 60 min gradient starting at
403 94 % solvent A (water/acetonitrile/formic acid 100 %/0 %/0.1 %, vol/vol/vol) and 6 % solvent B
404 (water/acetonitrile/formic acid 20 %/80 %/0.1 %, vol/vol/vol) for 4 min, then increasing the percentage
405 of solvent B to 44 % within 45 min followed by a 1 min step to 100 % B for additional 10 min. The mass
406 spectrometer was operated in data-dependent-mode with dynamic exclusion set to 60 s and a total cycle
407 time of 3 s. Full scan MS spectra were acquired in the Orbitrap (120,000 resolution, $2e5$ AGC target, 50 ms
408 maximum injection time). Most intense precursor ions with charge states 3 – 8 and intensities greater
409 than $5e3$ were selected for fragmentation using collision induced dissociation with 35 % collision energy.
410 Monoisotopic peak determination was set to peptide and MS/MS spectra were acquired in the linear ion
411 trap (rapid scan rate, $1e4$ AGC target).

412

413 **Supplementary Figures and Figure Legends**



414


415 **Figure S 1: Local resolution of cryo-EM structures.**

416 **(A, B)** Density maps of 46QHTT-HAP40 and 128QHTT-HAP40 complexes colored according to local
417 resolution. The maps were filtered according to the local resolution.


418 **(C)** FSC plots of the two structures. The FSC = 0.143 criterion was used for the estimation of the global
419 resolution.

420 Related to Figure 2.


A




B



C



D



430 **Figure S 3: Effects of polyQ expansion on overall crosslink patterns of HTT-HAP40 complexes.**

431 **(A, B, C)** Comparative representation of all crosslinks identified in three different **polyQ expanded** HTT-
432 HAP40 complexes, namely 17QHTT-HAP40 (A), 46QHTT-HAP40 (B) and 128QHTT-HAP40 (C). A uniform
433 numbering scheme based on the 17QHTT sequence was used. Crosslinks common to all three complexes
434 are represented by thick, black solid lines. Crosslinks identified in only two of the complexes are
435 represented by thin solid lines (17QHTT and 46QHTT, black; 17QHTT and 128QHTT dark grey; 46QHTT and
436 128QHTT, light grey). Crosslinks identified in only one of the complexes are depicted by dotted lines
437 (17QHTT, black; 46QHTT, dark grey; 128QHTT light grey). Only high-confidence crosslinks that were
438 reliably identified in at least two out of three biological replicates are shown (see methods for details).
439 Interlinks are shown as straight line, Intralinks as curved line and monolinks as a flag. The HTT N-HEAT
440 domain, bridge domain and C-HEAT domains are colored in blue, yellow and maroon, respectively. HAP40
441 is colored in purple. **(D)** Venn diagrams showing the overlap of crosslinks identified in the three different
442 HTT-HAP40 complexes **(A, B, C)**.

443 Related to Figure 3.

444

445 **Supplementary Tables and Table Legends**

446

	46Q-Huntingtin-HAP40 complex (EMD-30911) (PDB 7DXJ)	128Q-Huntingtin-HAP40 complex (EMD-30912) (PDB 7DXK)
Data collection and processing		
Magnification	105,000X	105,000X
Voltage (kV)	300	300
Electron exposure (e ⁻ /Å ²)	32	32
Defocus range (µm)	1.4-3.0	1.4-3.0
Pixel size (Å)	1.35	1.35
Symmetry imposed	C1	C1
Initial particle images (no.)	581'397	463'213
Final particle images (no.)	192'473	122'992
Map resolution (Å)	3.6	4.1
FSC threshold	0.143	0.143
Map resolution range (Å)	3.5-5.0	4.0-6.0
Refinement		
Map sharpening <i>B</i> factor (Å ²)	-140	-187
Model composition		
Non-hydrogen atoms	20491	20491
Protein residues	2.621	2.621
R.m.s. deviations		
Bond lengths (Å)	0.0076	0.0074
Bond angles (°)	1.38	1.30
Validation		
MolProbity score	1.66	1.70
Clashscore	4.80	5.93
Poor rotamers (%)	0.97	0.48
Ramachandran plot		
Favored (%)	93.86	94.60
Allowed (%)	5.90	5.24
Disallowed (%)	0.23	0.16

447

448 **Table S 1: Cryo-EM data collection, refinement and validation statistics.** Related to Figure 2.

449

450 **Table S 2: Crosslinking data.** Related to Figure 3.

451

452 References

- 453 Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W.,
454 Kapral, G.J., Grosse-Kunstleve, R.W., *et al.* (2010). PHENIX: a comprehensive Python-based system for
455 macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* *66*, 213-221.
- 456 Alexander, C.G., Wanner, R., Johnson, C.M., Breitsprecher, D., Winter, G., Duhr, S., Baaske, P., and
457 Ferguson, N. (2014). Novel microscale approaches for easy, rapid determination of protein stability in
458 academic and commercial settings. *Biochim Biophys Acta* *1844*, 2241-2250.
- 459 Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, C., Leavitt, B.R., Nance, M., Ross, C.A., Scahill,
460 R.I., Wetzel, R., *et al.* (2015). Huntington disease. *Nat Rev Dis Primers* *1*, 15005.
- 461 Bravo-Arredondo, J.M., Kegulian, N.C., Schmidt, T., Pandey, N.K., Situ, A.J., Ulmer, T.S., and Langen, R.
462 (2018). The folding equilibrium of huntingtin exon 1 monomer depends on its polyglutamine tract. *J Biol*
463 *Chem* *293*, 19613-19623.
- 464 Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W.,
465 Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom structure validation for
466 macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* *66*, 12-21.
- 467 Cisbani, G., and Cicchetti, F. (2012). An in vitro perspective on the molecular mechanisms underlying
468 mutant huntingtin protein toxicity. *Cell Death Dis* *3*, e382.
- 469 Combe, C.W., Fischer, L., and Rappsilber, J. (2015). xiNET: cross-link network maps with residue
470 resolution. *Mol Cell Proteomics* *14*, 1137-1147.
- 471 Difiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.P., Carraway,
472 R., Reeves, S.A., *et al.* (1995). Huntingtin Is a Cytoplasmic Protein Associated with Vesicles in Human and
473 Rat-Brain Neurons. *Neuron* *14*, 1075-1081.
- 474 Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr D*
475 *Biol Crystallogr* *60*, 2126-2132.
- 476 Finkbeiner, S. (2011). Huntington's Disease. *Cold Spring Harb Perspect Biol* *3*.
- 477 Guo, Q., Bin, H., Cheng, J., Seefeldter, M., Engler, T., Pfeifer, G., Oeckl, P., Otto, M., Moser, F., Maurer, M.,
478 *et al.* (2018). The cryo-electron microscopy structure of huntingtin. *Nature* *555*, 117-120.
- 479 Huang, B., Lucas, T., Kueppers, C., Dong, X., Krause, M., Bepperling, A., Buchner, J., Voshol, H., Weiss, A.,
480 Gerrits, B., *et al.* (2015). Scalable production in human cells and biochemical characterization of full-
481 length normal and mutant huntingtin. *PLoS One* *10*, e0121055.

482 Iacobucci, C., Piotrowski, C., Aebersold, R., Amaral, B.C., Andrews, P., Bernfur, K., Borchers, C., Brodie,
483 N.I., Bruce, J.E., Cao, Y., *et al.* (2019). First Community-Wide, Comparative Cross-Linking Mass
484 Spectrometry Study. *Anal Chem* *91*, 6953-6961.

485 Jung, T., Shin, B., Tamo, G., Kim, H., Vijayvargia, R., Leitner, A., Marcaida, M.J., Astorga-Wells, J., Jung, R.,
486 Aebersold, R., *et al.* (2020). The Polyglutamine Expansion at the N-Terminal of Huntingtin Protein
487 Modulates the Dynamic Configuration and Phosphorylation of the C-Terminal HEAT Domain. *Structure*
488 *28*, 1035-1050 e1038.

489 Leitner, A., Walzthoeni, T., and Aebersold, R. (2014). Lysine-specific chemical cross-linking of protein
490 complexes and identification of cross-linking sites using LC-MS/MS and the xQuest/xProphet software
491 pipeline. *Nat Protoc* *9*, 120-137.

492 Mastronarde, D.N. (2005). Automated electron microscope tomography using robust prediction of
493 specimen movements. *J Struct Biol* *152*, 36-51.

494 Newcombe, E.A., Ruff, K.M., Sethi, A., Ormsby, A.R., Ramdzan, Y.M., Fox, A., Purcell, A.W., Gooley, P.R.,
495 Pappu, R.V., and Hatters, D.M. (2018). Tadpole-like Conformations of Huntingtin Exon 1 Are
496 Characterized by Conformational Heterogeneity that Persists regardless of Polyglutamine Length. *J Mol*
497 *Biol* *430*, 1442-1458.

498 Pal, A., Severin, F., Lommer, B., Shevchenko, A., and Zerial, M. (2006). Huntingtin-HAP40 complex is a
499 novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease.
500 *J Cell Biol* *172*, 605-618.

501 Pardo, R., Molina-Calavita, M., Poizat, G., Keryer, G., Humbert, S., and Saudou, F. (2010). pARIS-htt: an
502 optimised expression platform to study huntingtin reveals functional domains required for vesicular
503 trafficking. *Mol Brain* *3*, 17.

504 Peters, M.F., and Ross, C.A. (2001). Isolation of a 40-kDa Huntingtin-associated protein. *J Biol Chem* *276*,
505 3188-3194.

506 Rohou, A., and Grigorieff, N. (2015). CTFFIND4: Fast and accurate defocus estimation from electron
507 micrographs. *J Struct Biol* *192*, 216-221.

508 Saudou, F., and Humbert, S. (2016). The Biology of Huntingtin. *Neuron* *89*, 910-926.

509 Scheres, S.H. (2012). RELION: implementation of a Bayesian approach to cryo-EM structure
510 determination. *J Struct Biol* *180*, 519-530.

511 Scheres, S.H., and Chen, S. (2012). Prevention of overfitting in cryo-EM structure determination. *Nat*
512 *Methods* *9*, 853-854.

513 Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G.P., Davies,
514 S.W., Lehrach, H., and Wanker, E.E. (1997). Huntingtin-encoded polyglutamine expansions form
515 amyloid-like protein aggregates in vitro and in vivo. *Cell* *90*, 549-558.

516 Seefelder, M., Alva, V., Huang, B., Engler, T., Baumeister, W., Guo, Q., Fernandez-Busnadiego, R., Lupas,
517 A.N., and Kochanek, S. (2020). The evolution of the huntingtin-associated protein 40 (HAP40) in
518 conjunction with huntingtin. *BMC Evol Biol* *20*, 162.

519 Vedadi, M., Niesen, F.H., Allali-Hassani, A., Fedorov, O.Y., Finerty, P.J., Jr., Wasney, G.A., Yeung, R.,
520 Arrowsmith, C., Ball, L.J., Berglund, H., *et al.* (2006). Chemical screening methods to identify ligands that
521 promote protein stability, protein crystallization, and structure determination. *Proc Natl Acad Sci U S A*
522 *103*, 15835-15840.

523 Vijayvargia, R., Epanand, R., Leitner, A., Jung, T.Y., Shin, B., Jung, R., Lloret, A., Singh Atwal, R., Lee, H., Lee,
524 J.M., *et al.* (2016). Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent
525 modulation of its structure and function. *Elife* *5*, e11184.

526 Vizcaino, J.A., Csordas, A., Del-Toro, N., Dianas, J.A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y.,
527 Reisinger, F., Ternent, T., *et al.* (2016). 2016 update of the PRIDE database and its related tools. *Nucleic*
528 *Acids Res* *44*, 11033.

529 Warner, J.B.t., Ruff, K.M., Tan, P.S., Lemke, E.A., Pappu, R.V., and Lashuel, H.A. (2017). Monomeric
530 Huntingtin Exon 1 Has Similar Overall Structural Features for Wild-Type and Pathological Polyglutamine
531 Lengths. *J Am Chem Soc* *139*, 14456-14469.

532 Zheng, S.Q., Palovcak, E., Armache, J.P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017). MotionCor2:
533 anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods*
534 *14*, 331-332.

535 Zuccato, C., Valenza, M., and Cattaneo, E. (2010). *Molecular Mechanisms and Potential Therapeutical*
536 *Targets in Huntington's Disease*, Vol 90.

537